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ABSTRACT
Introduction Non-compressible torso haemorrhage
(NCTH) carries a high mortality in trauma as many
patients exsanguinate prior to deﬁnitive haemorrhage
control. Resuscitative endovascular balloon occlusion of
the aorta (REBOA) is an adjunct that has the potential
to bridge patients to deﬁnitive haemostasis. However,
the proportion of trauma patients in whom REBOA may
be utilised is unknown.
Methods We conducted a population based analysis of
2012–2013 Trauma Audit and Research Network (TARN)
data. We identiﬁed the number of patients in whom
REBOA may have been utilised, deﬁned by an
Abbreviated Injury Scale score ≥3 to abdominal solid
organs, abdominal or pelvic vasculature, pelvic fracture
with ring disruption or proximal traumatic lower limb
amputation, together with a systolic blood pressure
<90 mm Hg. Patients with non-compressible
haemorrhage in the mediastinum, axilla, face or neck
were excluded.
Results During 2012–2013, 72 677 adult trauma
patients admitted to hospitals in England and Wales
were identiﬁed. 397 patients had an indication(s) and
no contraindications for REBOA with evidence of
haemorrhagic shock: 69% men, median age 43 years
and median Injury Severity Score 32. Overall mortality
was 32%. Major trauma centres (MTCs) received the
highest concentration of potential REBOA patients, and
would be anticipated to receive a patient in whom
REBOA may be utilised every 95 days, increasing to
every 46 days in the 10 MTCs with the highest
attendance of this injury type.
Conclusions This TARN database analysis has
identiﬁed a small group of severely injured, resource
intensive patients with a highly lethal injury that is
theoretically amenable to REBOA. The highest density of
these patients is seen at MTCs, and as such a planned
evaluation of REBOA should be further considered in
these hospitals.
INTRODUCTION
Haemorrhage is the leading cause of potentially
preventable death following traumatic injury.1–7
Non-compressible torso haemorrhage (NCTH),
deﬁned as vascular disruption to the axial torso
vessels, solid organs, pulmonary parenchyma or the
bony pelvis, accompanied by shock,8 has a morta-
lity of approximately 45%.9 10 A signiﬁcant
proportion of these deaths occur before the oppor-
tunity for deﬁnitive haemorrhage control in an
operating theatre or interventional radiology
suite.2 10 There is therefore a need for a haemor-
rhage control adjunct, to achieve temporary cessa-
tion of bleeding, until deﬁnitive haemostasis can be
achieved.
Resuscitative endovascular balloon occlusion of
the aorta (REBOA) involves the temporary occlu-
sion of the aorta, using a percutaneously deployed
intravascular balloon, usually inserted via the
femoral artery. REBOA has demonstrated potential
application in large animal models and several
human studies. In animal models of NCTH,
REBOA has been shown to improve survival,11 12
increase blood pressure (BP),11 13 14 brain oxygen-
ation and carotid arterial blood ﬂow.14 15 REBOA
has also been demonstrated to be superior to
haemostatic gauze in the control of pelvic haemor-
rhage.12 In two human case series, of 13 and 6
patients, survival from presumed lethal NCTH was
shown to be between 46% and 67%.16 17
However, more recent publication of a large, retro-
spective, propensity score matched data study from
the Japan Trauma Data bank suggested that the use
of REBOA in blunt abdominal trauma is associated
with increased mortality (OR of survival 0.3, 95%
CI 0.23 to 0.40).18 The decision to use REBOA in
this study was based on the physicians’ clinical deci-
sion making (ie, not according to a clinical practice
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Key messages
What is already known on this subject?
▸ Haemorrhage is the leading cause of
potentially survivable death in trauma.
▸ Resuscitative endovascular occlusion of the
aorta (REBOA) has been shown in large animal
models to improve survival in non-compressible
torso haemorrhage but early clinical data are
equivocal.
What might this study adds?
▸ The number of patients in England and Wales
in whom REBOA may be utilised is small, but
they have a mortality of 32%.
▸ The highest density of potential REBOA
patients is seen at major trauma centres.
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guideline), and the authors state that the results may reﬂect
REBOA being used in a ‘last ditch’ effort in otherwise unsal-
vageable patients. However, these data highlight the need to
better evaluate the potential beneﬁt or harm of REBOA before
widespread clinical implementation.
The decision to use REBOA should be part of a robust clinical
governance framework in order to ensure both high quality
patient care and the ability to make valid observations and/or
comparisons about the effectiveness of this novel therapy. Part
of this framework concerns training but to date there is no con-
sensus on the training requirement for REBOA.19 A number of
centres have described their own training packages,20–22 with
evidence that as little as 2 days of training,21 or didactic instruc-
tion followed by six REBOA insertions in a virtual reality suite,
is adequate.22 Some of the skills required for REBOA deploy-
ment (vascular access, endovascular wire placement, balloon
placement) may be translatable from existing trauma centre
experience (among emergency physicians, intensivists, vascular
surgeons and interventional radiologists) but the importance of
dedicated training within robust governance cannot be empha-
sised enough.
A 2015 review of the potential use of REBOA in exsanguinat-
ing haemorrhage suggests that this new technique should be
‘evaluated rigorously’ before universal acceptance.23 This paper
provides an algorithm to guide management of these patients, in
which REBOA may be considered, as local expertise permits,
but that emergency department thoracotomy and aortic cross
clamp is preferred. Bifﬂ et al’s23 recommendation in pelvic
haemorrhage however is that the use of REBOA should be the
preferred management option, particularly if there is a likely
delay to deﬁnitive haemostasis. There is a paucity of controlled
human data which quantiﬁes any beneﬁt or potential harm of
REBOA and a comparison with established medical manage-
ment—a randomised controlled trial is therefore urgently
required.
In planning future REBOA studies it will be important to
know the proportion of patients who have indications (and no
contraindications) to this intervention—this number is currently
unknown. Therefore, we have conducted a gap analysis, using
the Trauma Audit and Research Network’s (TARN—NHS
England and Wales trauma database) registry, and anatomical
injury scores, to identify the number of patients in whom
REBOA may have reasonably been utilised. The primary aim
was to identify the number of patients with an anatomical injury
and admission physiology that was theoretically amenable to
REBOA. The secondary aims included an analysis of injury pat-
terns, mortality, resources required for patient management and
the type of trauma hospital at which patients were ﬁrst
managed. This study will be used to inform the implementation
and further study of aortic balloon occlusion in patients with
traumatic haemorrhage.
METHODS
This was a retrospective analysis of the cohort of major trauma
patients presenting to hospitals in England and Wales between
1 January 2012 and 31 December 2013. Data were obtained
from TARN. TARN was established 25 years ago and now holds
the largest trauma registry in Europe. It is the national clinical
audit for trauma care, which collects data on patients with mod-
erate to major injuries from all trauma receiving hospitals in
England, Wales and the Republic of Ireland, with participation
from some hospitals across other parts of Europe. The informa-
tion is submitted electronically by each hospital to TARN via a
web based data collection system and follows the patient
pathway from prehospital to discharge, including key observa-
tions, interventions and outcome at 30 days. Inclusion criteria
were all adults (≥16 years old) with a known outcome who met
the TARN inclusion criteria (admission to hospital 3 days or
longer, intensive or high dependency care or transfer for further
specialist care). Patients with an Abbreviated Injury Scale (AIS)
score of 6 (an anatomically unsurvivable injury) in any body
region were excluded. During the study timeframe, 98% of hos-
pitals across England and Wales were submitting data to TARN.
Two zones of aortic occlusion have been described: zone 1
(Z1) occlusion—between the left subclavian artery and the
coeliac artery (for the management of exsanguinating abdominal
haemorrhage); zone 3 (Z3) occlusion—between the caudal renal
artery and the aortic bifurcation (for the management of exsan-
guinating pelvic or lower limb haemorrhage). There is no pub-
lished consensus on the indications or contraindications for the
use of REBOA. We therefore utilised methodology from a previ-
ous military combat study, aimed at identifying patients in
whom REBOA may have been utilised.24 This paper suggested
that Z1 occlusion was indicated in abdominal haemorrhage
(high grade solid organ injury, mesenteric disruption or injury
to a named vessel proximal to the aortic bifurcation) and that
Z3 occlusion was indicated for pelvic and/or groin haemorrhage
(pelvic fracture with ring disruption, traumatic amputation at or
near the hip or injury to a named vessel proximal to the femoral
segments).24 The AIS codes for these injuries were used to iden-
tify those with an indication for REBOA (all zones, Z1 and Z3)
(table 1).
Contraindications were identiﬁed in the same way, and in
general included non-compressible haemorrhage proximal to
the proposed zone of occlusion: thoracic aortic disruption and
arterial injury within the superior mediastinum, axilla and face
(table 1). Those patients with both an indication and a contra-
indication were placed in the contraindication group.
Physiological indication for REBOA was a hospital arrival sys-
tolic BP (SBP) <90 mm Hg.
In order to differentiate deaths due to haemostatic failure (as
opposed to neurological or multiorgan failure), fatalities were
dichotomised into early deaths (within 12 h of hospital arrival)
and late deaths (more than 12 h after hospital arrival). Although
it is acknowledged that severe neurological injury may result in
early death, those with a head AIS score of 6 (anatomically
unsurvivable traumatic brain injury) were excluded.
The Trauma Network in England became operational in April
2012. There are therefore 3 months in this study period, from
January 2012, in which hospitals were not ofﬁcially designated
as major trauma centres (MTCs) or trauma units (TU). In recog-
nition that MTCs were already planning for their new trauma
status at the start of this study, the patients they received in the
Table 1 Anatomical indications and contraindications to REBOA
Indications
ContraindicationsZone 1 Zone 3
High grade (AIS ≥3) injury High grade (AIS ≥3) injury NCTH in
Liver/kidney/spleen Pelvic fracture with ring
disruption
Superior
mediastinum
Mesenteric disruption Named pelvic vessel injury Axilla
Named abdominal
vessel injury
Traumatic amputation
at/near hip
Face or neck
AIS, Abbreviated Injury Scale score; NCTH, non-compressible torso haemorrhage;
REBOA, resuscitative endovascular balloon occlusion of the aorta.
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ﬁrst 3 months of this study were included in the MTC group.
Patients received at hospitals who were to become TUs in April
2012 were included in the TU group. To date, Wales does not
have a Trauma Network, and therefore all trauma patients in
Wales were included in the TU group.
Data analysis
Basic demographics, and admission physiology and injury data
are reported as number (%), mean (95% CI) or median (IQR).
Continuous data were analysed using the Mann–Whitney U test,
and categorical data were analysed using the χ2 test. All hypoth-
eses testing were performed with SPSS V.22.0 (IBM Corp.
Armonk, New York, USA). Comparisons of resource utilisation
was performed by calculating OR (95% CI) between groups with
Prism V.6.0f (Graphpad Software Inc, La Jolla, California, USA).
RESULTS
During 2012 and 2013, 72 677 adult patients were included in
the TARN registry: 3543 (4.9%) patients had anatomical indica-
tions for, and no contraindications to, REBOA, and 397
(0.55%) of these presented in shock (REBOA group, ﬁgure 1).
The frequency of anatomical indications in this cohort is
described in table 2.
When analysed by zone of occlusion, 201 (50.6%) patients
would have required Z1 occlusion, 161 (40.6%) patients would
have required Z3 occlusion and 35 (8.8%) patients had inde-
pendent indications for both Z1 and Z3 occlusion. For further
analyses, and to maintain clinical relevance, those with indica-
tions for both Z1 and Z3 occlusion have been included in the
Z1 subgroup, as in order to control haemorrhage in both areas,
a proximal (Z1) aortic balloon would be required.
Demographics
The REBOA group consisted of 273 (68.8%) male patients,
with a median age of 43 (27.8 to 60.2) years. More than 90%
had a blunt mechanism of injury, and over half were injured in a
road trafﬁc collision (table 3).
Compared with the TARN patients with no indication for
REBOA, the REBOA group were younger, more likely to be
male, more likely to have a penetrating mechanism of injury
(9.3% (95% CI 6.5 to 12.2) vs 2.8% (2.7 to 2.9)), more likely
to have been injured in a road trafﬁc collision (54.7% (49.8 to
59.6) vs 19.1 (18.8 to 19.4)), less likely to have been injured in
a fall under 2 m (9.6% (6.7 to 12.5) vs 56.9% (56.5 to 57.3)),
have a higher Injury Severity Score (ISS), more likely to have
had a thoracic injury (62.0% (57.2 to 66.7) vs 17.4% (17.1 to
17.6)) and more likely to have an abdominal injury (67.8%
(63.2 to –72.4) vs 0.8% (0.8 to 0.9); all p<0.001) (table 3).
Injury patterns
The Z3 subgroup were statistically more likely to have been
injured in a fall over 2 m than the Z1 subgroup (29.2% (22.2 to
36.2) vs 13.1% (8.8 to 17.4); p<0.001). They were also more
likely to be older (p=0.02) and have a higher ISS (p<0.01)
(table 3). However, there were no other signiﬁcant differences
in demographics, mechanism of injury or admission physiology
between these subgroups.
Resource utilisation
Two hundred and eighteen (54.9%) patients in the REBOA
group received a blood transfusion in the ﬁrst 24 h from admis-
sion compared with 2634 (4.0%) of those with no indication
for REBOA and 3708 (5.3%) patients in the entire cohort. The
median number of units of packed red cells and fresh frozen
plasma used in the REBOA group in the ﬁrst 24 h was 6.3–10
The REBOA group (n=397) required signiﬁcantly more
resources than those with no indication for REBOA
(n=69 134). The odds of requiring a thoracotomy, laparotomy,
embolisation, surgical pelvic stabilisation, activation of a trauma
team, activation of a massive transfusion protocol, a blood
transfusion within 24 h of hospital arrival and administration of
tranexamic acid were all signiﬁcantly higher in the REBOA
group (all p<0.001). The ORs produced between these two
groups were high (eg, the OR for activation of a massive trans-
fusion protocol was 41), which suggests the comparison is of
limited usefulness. We therefore further compared the REBOA
group (those with anatomical indications, no contraindications
and haemodynamically shocked, n=397) with those with an
indication for REBOA without evidence of shock (n=3100). In
this latter comparison, the REBOA group were still signiﬁcantly
more likely to require all the examined resources (p<0.001)
with the exception of embolisation (ﬁgure 2). This result indi-
cates a group of patients which, although small in number, place
a heavy resource burden on the health service.
Mortality
The overall mortality of the REBOA group was 32.0% (n=127
out of 397). There was no statistical mortality difference
between the Z1 and Z3 subgroups (34.7% (28.7 to 40.8) vs
28.0% (21.0 to 34.9); p=0.20).
We dichotomised the deaths into early (≤12 h of hospital
arrival, 62.2%) and late (>12 h after hospital arrival, 37.8%)
groups in order to better differentiate deaths due to haemor-
rhage (and therefore potentially amenable to REBOA). This
evaluation showed that survivors had a lower ISS than all deaths
(p<0.001), and that there was no difference in ISS between
early and late deaths (p=0.90). Severe traumatic brain injury
(TBI) was more likely in deaths than survivors (43.3% (34.7 to
51.5) vs 13.7% (9.6 to 17.8); p<0.001) but there was no
Figure 1 Study inclusion and exclusion criteria. CPR, cardiopulmonary
resuscitation; REBOA, resuscitative endovascular balloon occlusion of
the aorta; SBP; systolic blood pressure; TARN, Trauma Audit and
Research Network.
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difference between early and late deaths (43.0% (32.1 to 53.9)
vs 43.8% (29.8 to 57.8); p=1.0).
Early deaths were more likely than late deaths to have admis-
sion physiology consistent with traumatic cardiac arrest (TCA)
(lower pulse, lower SBP, lower Glasgow Coma Scale score;
p<0.001). In the early death group, 31 (39.2%) patients had an
SBP of 0, and 28 (35.4%) had a heart rate of 0 (table 4).
Type of receiving hospital
The majority (64.5%) of TARN patients were initially admitted
to TUs. However, two-thirds of the REBOA group were primar-
ily conveyed to a MTC (table 5).
This concentration of patients in whom REBOA may have
been applied at MTCs is further increased by the fewer number
of MTCs (32 vs 223 TUs). The mean number of REBOA
Table 2 Frequency of anatomical indications for REBOA in this cohort, with and without the presence of haemorrhagic shock
Zone 1 indication (n=236) Zone 3 indication (n=196)*
AIS ≥3 injury to
Liver/kidney/
spleen
Mesenteric
disruption
Named vessel
injury
Pelvic
fracture
Named vessel
injury
Amputation at
or near hip
Anatomical indications for REBOA 1530 58 111 1932 167 2
Anatomical indications for REBOA
(no contraindications and not shocked)
1503 48 91 1728 131 2
REBOA group (n (%)) 218 (92.4) 10 (4.2) 16 (6.8) 177 (90.3) 29 (14.8) 0
REBOA group, patients with an anatomical indication for REBOA, with no anatomical contraindications and with physiological evidence of hypovolaemic shock.
*Patients with both zone 1 and zone 3 anatomical indications (n=35) are included in both zones’ denominators.
AIS, Abbreviated Injury Scale score; REBOA, resuscitative endovascular balloon occlusion of the aorta.
Table 3 Demographics, injury pattern and physiology on arrival to hospital for TARN patients without an indication for REBOA, those with an
anatomical and physiological indication and no contraindications for REBOA, and by zone of aortic occlusion indicated
No indication for REBOA
REBOA
(zones 1 and 3)
REBOA
(zone 1)
REBOA
(zone 3)
No of patients 69 134 397 236 161
Gender (n (%))
Men 38 485 (55.7) 273 (68.8) 163 (69.1) 110 (68.3)
Women 30 649 (44.3) 124 (31.2) 73 (30.9) 51 (31.7)
ISS (median (IQR)) 9.0 (9.0–16.0) 32.0 (20.0–45.0) 29.0 (18.0–43.0) 36.0 (25.0–45.0)
Age (years) (median (IQR)) 62.3 (44.0–80.6) 43.0 (27.8–60.2) 40.7 (27.2–57.2) 48.0 (29.8–65.3)
Mode of injury ( n (%))
Blunt 67 211 (97.2) 360 (90.7) 215 (91.1) 145 (90.1)
Stab 1241 (1.8) 35 (8.8) 20 (8.5) 15 (9.3)
Gunshot wound 139 (0.2) 1 (0.3) (0) 1 (0.6)
Other penetrating 543 (0.8) 1 (0.3) 1 (0.4) (0)
Mechanism of injury (n (%))
RTC 13 204 (19.1) 217 (54.7) 132 (55.9) 85 (52.8)
Fall >2 m 9491 (13.7) 78 (19.6) 31 (13.1) 47 (29.2)
Fall <2 m 39 335 (56.9) 38 (9.6) 28 (11.9) 10 (6.2)
Shooting/stabbing 1380 (2) 36 (9.1) 20 (8.5) 16 (9.9)
Blow(s) 3700 (5.4) 21 (5.3) 21 (8.9) (0)
Other 2024 (2.9) 7 (1.8) 4 (1.7) 3 (1.9)
Injury pattern (AIS 3+) ( n (%))
Head 16 934 (24.5) 92 (23.2) 50 (21.2) 42 (26.1)
Thorax 11 999 (17.4) 246 (62) 160 (67.8) 86 (53.4)
Abdomen 571 (0.8) 269 (67.8) 236 (100) 33 (20.5)
Upper limb 1266 (1.8) 5 (1.3) 3 (1.3) 2 (1.2)
Lower limb 20 198 (29.2) 89 (22.4) 32 (13.6) 57 (35.4)
Pelvis 0 (0.0) 177 (44.6) 34 (14.4) 143 (88.8)
Other 762 (1.1%) 7 (1.8) 2 (0.8) 5 (3.1)
Admission physiology (median (IQR))
SBP (mm Hg) 138 (121– 155) 78 (64–85) 78 (63–85) 78.5 (68–85)
Heart rate 82 (70–94) 92.5 (72–116) 91 (71–116) 99 (73–116)
GCS 15 (15–15) 14 (3–15) 14 (3–15) 14 (9–15)
The REBOA group had a high burden of injury, demonstrated by a median ISS of 32 [20–45], and an overall mortality of 32.0%.
AIS, Abbreviated Injury Scale; GCS, Glasgow Coma Scale; ISS, Injury Severity Score; REBOA, resuscitative endovascular balloon occlusion of the aorta; RTC, road traffic collision; SBP,
systolic blood pressure; TARN, Trauma Audit and Research Network.
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patients per hospital during the study period was substantially
higher in MTCs than TUs (7.7 and 0.7, respectively) (table 5).
There was a large range in the number of potential REBOA
patients seen at each MTC (between 0 and 34 patients during
the study period). We therefore included a further analysis of
the 10 MTCs that had the highest incidence of potential
REBOA patients—these 10 MTCs saw 40.3% of the REBOA
group patients in the study (table 5). According to these data we
would expect, on average, that each MTC would see a patient
in whom REBOA may be utilised every 95 days, reducing to 1
every 46 days in the 10 MTCs with the highest presentation of
this injury type.
DISCUSSION
This is the ﬁrst population based civilian study of trauma
patients who had an injury pattern and physiology in which
REBOA may have been considered. Our analysis demonstrates
that, across England and Wales, a population of 57 million,
there were approximately 200 such patients per year. While this
number is small, these patients were predominantly young, and
their mortality was high (one-third died).
Some of these deaths might have been preventable with more
prompt haemorrhage control. More than half of deaths
occurred within 12 h of hospital arrival which, in the absence
of unsurvivable TBI (which were excluded), may have been due
to incomplete haemostasis. However, patients who died early
also had a higher burden of injury (including TBI) compared
with survivors, and more profound physiological derangement
(39% had admission physiology consistent with TCA). The
potential beneﬁt of REBOA in the clinical setting of TCA is
unknown. There is a single published description of successful
REBOA resuscitation in a patient with pulseless electrical
activity.17 However, this patient arrived in the emergency
department with an SBP of 60 mm Hg and subsequently dete-
riorated, suggesting a low cardiac output state with a perfusing
cardiac rhythm at the time of intervention. In patients without a
perfusing cardiac rhythm, REBOA (together with high volume
ﬂuid resuscitation) is unlikely to be an effective management
strategy. Furthermore, the technical skill required to deploy
REBOA in this situation should not be underestimated. Earlier,
including prehospital, haemorrhage control is likely to infer a
better chance of survival.
The REBOA group, in addition to a high mortality, required
considerable trauma resources, both procedural (eg, laparotomy)
and logistical (eg, blood transfusion). While the use of REBOA
would not reduce the requirement for deﬁnitive haemostasis
(and indeed might increase it, if more patients are alive to
receive it), it is postulated that it could deliver a more haemo-
dynamically stable patient to the proceduralist, and perhaps
therefore reduce the total blood transfusion requirements.
A large number of patients in whom REBOA may have been
utilised were conveyed to MTCs, and received by a trauma
team. The time period of this study includes the date of imple-
mentation of the Trauma Network in April 2012, and as such
the proportion of REBOA patients currently seen at MTCs is
likely to be slightly greater than we have reported. This is
encouraging for potential future intervention, as admission to a
hospital capable of providing deﬁnitive care should optimise
outcomes. This should also assist with the adoption of REBOA
into clinical practice, as members of the trauma team in an
MTC should already have, or could be taught, many of the
necessary skills. Previous evaluation of two REBOA training
packages suggests that 1–2 days of bespoke training may be
adequate for the endovascular interventional novice.21 22 The
Figure 2 The odds of receiving a trauma intervention for patients with an anatomical indication for resuscitative endovascular balloon occlusion of
the aorta and shocked, versus those with an anatomical indication but without evidence of shock. MTP, massive transfusion protocol.
Table 4 A hospital arrival demographic, physiological and serious traumatic brain injury comparison of REBOA patients; compared as survivors,
early deaths (≤12 h) and late deaths (>12 h)
Survivors Early deaths Late deaths
n 270 79 48
Age (median (IQR)) 42.1 (27.6–59.4) 37.3 (25.5–56.7) 57.3 (41.8–80.2)
ISS (median (IQR)) 25.0 (17.0–41.0) 43.0 (33.0–50.0) 43.0 (29.0–50.0)
Heart rate (median (IQR)) 95.0 (77.0–116.0) 34.5 (0.0–115.0) 101.0 (80.0–113.0)
SBP (median (IQR)) 80.0 (70.0–85.0) 0.0 (0.0–77.0) 75.5 (63.0–82.0)
GCS (median (IQR)) 15.0 (14.0–15.0) 3.0 (3.0–3.0) 9.5 (3.0–15.0)
AIS 3+ head injury (n (%)) 37 (13.7) 34 (43.0) 21 (43.8)
AIS, Abbreviated Injury Scale; GCS, Glasgow Coma Scale; ISS, Injury Severity Score; REBOA, resuscitative endovascular balloon occlusion of the aorta; SBP, systolic blood pressure.
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level of skill to successfully insert a large (currently 12 F) arter-
ial access sheath in a profoundly hypovolaemic patient should
not be underestimated, although increasing use of ultrasound
has helped to reduce the reported median REBOA insertion
time to between 4 and 5 min in a porcine model.25 While it is
likely that this time to REBOA inﬂation is less than the time to
obtain haemostasis in an operating theatre or interventional
radiology suite, we are unable to ﬁnd contemporary data to
support this. However, we do not believe that REBOA should
be considered in isolation—it is at best a temporary measure to
deliver a more stable patient to deﬁnitive haemostasis, and in
the respect of interventional radiology, an already established
arterial access point inferior to the occlusion.
The concentration of REBOA patients in MTCs should also
facilitate the much needed further evaluation of this technique for
managing haemorrhage. The initial clinical reports of REBOA
have given a mixed picture; it is conceptually attractive, and
further organised prospective research is required to determine
the beneﬁts and harms of the technique against current practice
(emergency department thoracotomy, laparotomy, extraperitoneal
pelvic packing or any other strategy) without the use of REBOA.
However, our study does highlight a potential difﬁculty with
future study design—the small number of patients will make it
difﬁcult for any single centre to accumulate sufﬁcient institutional
experience to properly evaluate REBOA. Collaboration and
innovative study design will therefore be essential.
This study has a number of limitations. The most important is
that it is based on a retrospectively applied deﬁnition, compris-
ing anatomical injury scores and admission physiological para-
meters. Anatomical injury scores are not available to clinicians
as patients arrive in the emergency department; in reality, deci-
sions are made on the basis of clinical ﬁndings, particularly in
the context of exsanguinating haemorrhage, and it is not known
how well our epidemiological deﬁnition would correlate with
the clinical decision to use REBOA, or indeed a REBOA clinical
practice guideline. Furthermore, the potential harm of REBOA
is also unknown, and therefore a comparison with conventional
haemostasis techniques (thoracotomy, laparotomy and interven-
tional radiology) without REBOA should be made.
The most important confounder of haemorrhage mortality is
TBI, and although we tried to limit the effect of this by exclud-
ing the most severe brain injuries, it is impossible to remove
altogether. It is intriguing to hypothesise that REBOA, by
increasing cerebral perfusion, might assist in mitigating second-
ary brain injury. However, there are currently no human data to
support this concept.
Response to resuscitation is not well recorded in the TARN
registry, and it is therefore possible that even those patients
who presented in profound hypotension responded to
conventional management, thereby not requiring REBOA
(although clinical differentiation may be extremely challen-
ging). The net effect of these limitations would be an overesti-
mation of the true number of patients who might have been
considered for REBOA. However, the TARN registry is not a
complete record of all trauma patients admitted to hospitals in
England and Wales. During the period of this study, while all
MTCs submitted data to TARN, data submission is not always
complete. Furthermore, the use of SBP 90 mm Hg as a
measure of haemorrhagic shock is questionable. There were
119 patients in this study with an anatomical indication for
REBOA who underwent massive transfusion, but who did not
present with an SBP <90 mm Hg—the role of REBOA in this
group of patients is unknown, and presents potential difﬁculty
in writing clinical practice guidelines.
Outwith REBOA there are other non-conventional strategies
that have been shown to improve survival in exsanguinating
trauma, including bypassing the emergency department and com-
mencing resuscitation simultaneously to surgical haemostasis in
the operating theatre. This technique has further evolved in recent
military trauma care and, owing to the geographical layout of the
UK military hospital in Afghanistan, has been termed ‘right turn
resuscitation’. Data from the UK military have demonstrated that
while there was no observed difference in survival from right turn
resuscitation, there was a signiﬁcant increase in the number of
unexpected survivors.26 In addition to REBOA there are a number
of other strategies, currently in different stages of development,
aimed at managing NCTH, including selective aortic arch perfu-
sion, emergency preservation and resuscitation, abdominal foam
and resuscitation with angiography percutaneous treatments and
operative resuscitations. Ideally the future utility of REBOA
should also be measured against these strategies.
In summary, despite some limitations, this study has suc-
ceeded in identifying and characterising a small group of
severely injured, resource intensive patients with a highly lethal
injury pattern that is theoretically amenable to REBOA. The
highest density of these patients is seen at MTCs, and as such a
planned evaluation of REBOA should be further considered in
these hospitals alongside other conventional and non-
conventional management of NCTH.
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